Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
earnings-consensus: Archive
Does Griffon (GFF) Have the Potential to Rally 25.56% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 25.6% upside potential for Griffon (GFF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GFFNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 133.6% upside potential for Prime Medicine, Inc. (PRME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRMEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Silicon Motion (SIMO) Could Rally 25.56%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 25.6% upside potential for Silicon Motion (SIMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SIMOPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Shutterstock (SSTK) Could Surge 35.36%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 35.4% upside potential for Shutterstock (SSTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SSTKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Copa Holdings (CPA) Could Surge 46.75%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46.8% in Copa Holdings (CPA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CPANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Nordson (NDSN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Nordson (NDSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NDSNNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
XP Inc.A (XP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
XP Inc.A (XP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XPNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: American Resources Corporation (AREC) Q1 Earnings Expected to Decline
by Zacks Equity Research
American Resources (AREC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARECNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Nu Holdings Ltd. (NU) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Nu (NU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NUNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Transcat, Inc. (TRNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Transcat (TRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TRNSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STROPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VCYTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CLPTNo Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 34.27% Upside in SolarWinds (SWI): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for SolarWinds (SWI) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SWIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OPRXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 141% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RNACNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 78.65% Upside in IonQ (IONQ): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 78.7% upside potential for IonQ (IONQ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IONQNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Green Thumb Industries Inc. (GTBIF) Could Rally 42.3%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Green Thumb Industries Inc. (GTBIF) points to a 42.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GTBIFPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
IMVTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 39.04% Upside in Bumble (BMBL): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Bumble (BMBL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BMBLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 45.31% Upside in Newpark (NR): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.3% in Newpark (NR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NRPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 120.45%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 120.5% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BWAYNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 51.83% Upside in ARKO (ARKO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in ARKO (ARKO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ARKOPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GHRSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does TrueBlue (TBI) Have the Potential to Rally 81.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 81.3% in TrueBlue (TBI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TBIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate